WaveMan
WaveMan · Company
BFRG · Bullfrog Ai Holdings, Inc.
> Search tickers & screens ⌘K
LIVE
← All companies

BFRG BullFrog AI (BFRG) Insider Trading, Ownership & Congress Trades

Pharma & Biotech · Pharmaceutical preparations · CIK 0001829247
Quote by TradingView
C-suite buying · 2
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
17
13F, latest reported quarter

What the filings say about BFRG

Insiders, 180 days
+$71.3K net bought
2 buyers

BullFrog AI insider trades (Form 4)

Form 4 buys and sells (codes P and S). Grants, option exercises and conversions excluded.

Over the last 180 days, BullFrog AI Holdings, Inc. insiders bought a net $71.3K of stock across 39 Form 4 purchases and sales, with 2 insiders buying. Source: SEC Form 4 filings, as of 2026-10-28.

Insider
Filed
Shares
Value
Since filing
Singh Vininder
Chief Executive Officer
BUY
2026-09-22 SEC
75,000
$44.9K
-50.0%
Context
  • 36 earlier Form 4 trades (code P or S) here by this insider (36 sales), the last on Jul 7, 2025.
  • The trade is 3.1% of the 2,442,446 shares held after it.
  • 1 other insider bought within 30 days.
  • 17 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Executive Officer Singh Vininder bought about $44.9K of BFRG on Sep 22, 2026, the largest insider purchase at the company on our record; 1 other insider bought within 30 days and 17 funds added in the latest 13F quarter.
Blacher Joshua
Chief Financial Officer
BUY
2026-09-22 SEC
50,000
$26.4K
-50.0%
Context
  • First Form 4 purchase or sale (code P or S) here by this insider on our record.
  • The trade is 76.9% of the 65,000 shares held after it.
  • 1 other insider bought within 30 days.
  • 17 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Financial Officer Blacher Joshua bought about $26.4K of BFRG on Sep 22, 2026, the largest insider purchase at the company on our record; 1 other insider bought within 30 days and 17 funds added in the latest 13F quarter.
Singh Vininder
Chief Executive Officer
SELL
2025-07-08 SECtraded 2025-07-07
29,002
$43.5K
-68.1%
Context
  • 35 earlier Form 4 trades (code P or S) here by this insider (35 sales), the last on Apr 4, 2025.
  • The trade is 1.3% of the 2,292,446 shares held after it.
  • No other insider sold within 30 days.
  • 17 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Executive Officer Singh Vininder sold about $43.5K of BFRG on Jul 7, 2025, the largest insider sale at the company since 2024; 17 funds added in the latest 13F quarter.
Singh Vininder
Chief Executive Officer
SELL
2025-04-04 SEC
5,895
$7.7K
-68.7%
Context
  • 34 earlier Form 4 trades (code P or S) here by this insider (34 sales), the last on Apr 3, 2025.
  • The trade is 0.3% of the 2,342,446 shares held after it.
  • No other insider sold within 30 days.
  • 17 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Executive Officer Singh Vininder sold about $7.7K of BFRG on Apr 4, 2025; 17 funds added in the latest 13F quarter.
Singh Vininder
Chief Executive Officer
SELL
2025-04-03 SEC
27,958
$40.3K
-63.4%
Context
  • 33 earlier Form 4 trades (code P or S) here by this insider (33 sales), the last on Apr 2, 2025.
  • The trade is 1.2% of the 2,348,341 shares held after it.
  • No other insider sold within 30 days.
  • 17 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Executive Officer Singh Vininder sold about $40.3K of BFRG on Apr 3, 2025, the largest insider sale at the company since 2024; 17 funds added in the latest 13F quarter.
39 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
See all insider buying · insider selling
Showing the latest few. to see 34 more transactions and use the screener and CSV export. We store only your email; there is no password.
Seven facts, ranked against the sector · Rank is not a forecast
Insiders
net +$71.3K over 180 days
+$71.3K over 90 days · +$44.9K of it by a 10%+ holder
more than 75% of Pharma & Biotech
Congress
no House purchase disclosed in the last 12 months
Funds
17 funds bought in last quarter
below 71% of Pharma & Biotech
Revenue
+79.5% year over year
more than 83% of Pharma & Biotech
Margin
no margin: no revenue reported
Buybacks
no share repurchases reported
Short interest
6.3% of the float short (float per yahoo 2026-10-27) · 1.0 days to cover · settled 2026-10-15
more than 54% of Pharma & Biotech
What changed in the last 30 days
Nothing new filed in the last 30 days

Watch BFRG

A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.

The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
-66.3%12M
-70%-40%-10%+19%2025-102025-122026-022026-042026-062026-082026-10 2026-09-22 · Singh Vininder bought $44.9K2026-09-22 · Blacher Joshua bought $26.4K
Insider buy
Indexed to 100, dividend-adjusted, not a price chart. When a name files heavily, the largest trades are drawn first.

Who owns BFRG: institutional holders (13F)

13F holdings, latest reported quarter
CITADEL ADVISORS LLC
361,546 sh
$256.7K
J. Safra Sarasin Holding AG
113,720 sh
$191.1K
VANGUARD FIDUCIARY TRUST CO
106,484 sh
$75.6K
GEODE CAPITAL MANAGEMENT, LLC
104,928 sh
$74.5K
VANGUARD CAPITAL MANAGEMENT LLC
91,596 sh
$65.0K

Congress trades in BFRG

No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.

Activist and 5% holders (13D/13G)

No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.

BFRG planned insider sales (Form 144)

No planned-sale notices
No insider has filed to sell. Watch this after a run-up.

BFRG mutual fund holders (N-PORT)

Funds ranked by the share of their own portfolio in this stock (N-PORT).
Fidelity Extended Market Index Fund
$43.6K position · as of 2026-05-31
0.0%
VANGUARD EXTENDED MARKET INDEX FUND
$48.1K position · as of 2026-06-30
0.0%
Fidelity Nasdaq Composite Index Fund
$2.6K position · as of 2026-05-31
0.0%
Fidelity Series Total Market Index Fund
$5.4K position · as of 2026-05-31
0.0%
Fidelity Total Market Index Fund
$5.2K position · as of 2026-05-31
0.0%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M · % is the share of the fund's own portfolio
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
Insiders are net buyers of their own stock.
The record shows a net $71.3K bought by insiders over 180 days, 17 funds added last quarter. Each figure is a federal filing, dated the day it went public.
Backtest this pattern Open the screener
Same sector, ranked by filing activity
Sector by SEC SIC code
UTHRCPIXMRNAREGNLLYALNYMDGLCITRDNAVRTXNUVLTWST

BFRG financials

Revenue growth
+79.5%
XBRL, annual
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
n/a
fewer than four consecutive quarters of revenue filed
Net margin, TTM
n/a
needs four consecutive quarters of both revenue and net income
Free cash flow, TTM
n/a
capex not filed for the four quarters
Debt to equity
0.01x
current debt only, 2025-09-30 (9 months older than the period end); equity 2026-06-30
Cash flow to debt
-98.90x
TTM operating cash flow over current debt only, 2025-09-30 (9 months older than the period end)
Return on equity
-130.7%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets
-113.5%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on invested capital
n/a
tax provision or pre-tax income not filed for the four quarters
Return on capital employed
-133.0%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
P/E, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Enterprise value
$1.9M
market value at close 2026-10-27 on 2026-08-13 shares, plus current debt only, 2025-09-30 (9 months older than the period end), minus cash 2026-06-30
FCF yield
n/a
capex not filed for the four quarters
PEG, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Price as of 2026-10-27. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
2025-122024-122023-122022-12
Revenue$116.7Kn/a$65.0K$10.0K
Gross profit$21.9Kn/a$59.8K$9.2K
Operating income-$6.6M-$7.2M-$5.4M-$2.5M
Net income-$6.5M-$7.0M-$5.4M-$2.8M
EPS (diluted)-0.63-0.85-0.89-0.70
Operating cash flow-$5.5M-$5.6M-$6.0M-$910.9K
Cash$2.2M$5.4M$2.6M$57.7K
SEC XBRL, fiscal years, as known on 2026-10-28

BFRG Stock Sonar score 6/7 axes

Find similar shapesCompare

BFRG ranks highest on growth (83rd percentile) and insider conviction (77th), and lowest on profitability (22nd), among Pharma & Biotech peers.

ProfitHealthGrowthInsidersInstitutionsRisk
Profitability
22
Inputs
  • Return on equity-130.7% · 26 pct, sector of 545
  • Return on assets-113.5% · 21 pct, sector of 691
  • Return on invested capitaltax provision or pre-tax income not filed for the four quarters
  • Return on capital employed-133.0% · 19 pct, sector of 576
Financial health
43
Inputs
  • Debt to equity0.01x · 77 pct, sector of 352
  • Cash flow to debt-98.90x · 8 pct, sector of 371
Growth
83
Inputs
  • Revenue growth, YoY+79.5% · 83 pct, sector of 505
  • Backlog growth, YoYno backlog line filed, or no year-earlier backlog
Insider conviction
77
Inputs
  • Net Form 4 buying (codes P and S), 180d$71K · 74 pct, sector of 429
  • Insider buyers, 180d2 · 81 pct, sector of 438
Institutional and government
29
Inputs
  • Funds adding, latest quarter17 · 29 pct, sector of 698
  • Congress net buyers, 365dno Congress trades in 365 days
  • Federal contracts, 180dno federal contracts in 180 days
  • Lobbying spend, 4 quartersno lobbying filings in the last four quarters
Risk and compliance
53
Inputs
  • Short interest, % of float+6.3% · 53 pct, sector of 816
  • Recalls per $1B revenue, 3yrevenue under $50M or not filed, so a count cannot be scaled to size
  • EPA cases per $1B revenue, 5yrevenue under $50M or not filed, so a count cannot be scaled to size
  • New text in Risk Factors, latest 10-Kneeds two 10-Ks with a Risk Factors section (not 20-F filers or stubs)
1 not measured: US patents
  • US patents needs 1 of 2 inputs, 0 present: patent data not loaded yet

6 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored

BFRG filings, in plain words

Are BullFrog AI insiders buying or selling BFRG?

In the 180 days to 2026-10-28, BullFrog AI insiders were net buyers, a net $71.3K across purchases and sales reported on Form 4, by 2 buyers.

Read the full summary

In the 180 days to 2026-10-28, BullFrog AI insiders were net buyers of BFRG, a net $71.3K across purchases and sales reported on Form 4 by 2 buyers. Most of that figure, $44.9K, came from a holder of 10% or more rather than an officer or director. 2 different insiders reported purchases within the last 90 days, a cluster buy, which is rarer than a single purchase. Each figure is counted from SEC and House filings as of 2026-10-28, dated the day the filing was made public.

Explore insider trading and ownership data

Every company we track, ranked by each kind of filing
Insider buyingInsider sellingCongress stock tradesActivist 13D stakesForm 144 planned salesCEO pay vs performanceAll companies